Physician profile
Charmi Patel
NPI 1831432863
$5,578.84
in general payments reported to CMS, 2019-2025
28 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.41 · 2020: $233 · 2021: $682 · 2022: $453 · 2023: $490 · 2024: $1,561 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,117 · Consulting Fee: $25.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,117.20 |
| Consulting Fee | $25.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $792.58 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Alk-Abello, INC | $695.48 | 2020-2023 | Odactra |
| Glaxosmithkline, LLC. | $617.02 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $610.33 | 2021-2025 | Cuvitru, Takhzyro, Glassia |
| Genzyme Corporation | $456.19 | 2022-2025 | |
| Csl Behring | $446.54 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $246.78 | 2021-2025 | Xembify |
| Optinose US, INC. | $184.84 | 2022-2025 | |
| Amgen INC. | $184.40 | 2023-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $168.81 | 2021-2025 | Orladeyo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.94 | 2020 | |
| Pfizer INC. | $139.31 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $119.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $105.90 | 2022-2024 | Dupixent |
| Kaleo, INC. | $87.86 | 2021-2024 | Auvi-Q |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $86.23 | 2021-2025 | Xolair |
| Cycle Pharmaceuticals INC | $67.91 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $55.56 | 2023-2025 | Ryaltris |
| Incyte Corporation | $52.81 | 2022-2023 | Opzelura |
| Organon LLC | $50.84 | 2025 | |
| Galderma Laboratories, L.P. | $45.07 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $37.61 | 2024-2025 | Ruconest |
| Phadia US INC. | $37.21 | 2024 | Immunocap |
| Leo Pharma INC. | $36.27 | 2024 | Adbry |
| Adma Biomanufacturing LLC | $25.99 | 2025 | |
| Aimmune Therapeutics, INC. | $25.00 | 2022 | |
| X4 Pharmaceuticals, INC. | $22.02 | 2025 | Xolremdi |
| Ars Pharmaceuticals Operations, INC. | $20.51 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.